Wall Street Zen Upgrades Niagen Bioscience (NASDAQ:NAGE) to “Buy”

Niagen Bioscience (NASDAQ:NAGE) was upgraded by Wall Street Zen from a “hold” rating to a “buy” rating in a research report issued on Saturday.

A number of other research analysts have also weighed in on NAGE. Canaccord Genuity Group dropped their target price on Niagen Bioscience from $14.00 to $13.00 and set a “buy” rating on the stock in a report on Thursday, March 5th. Weiss Ratings reiterated a “hold (c)” rating on shares of Niagen Bioscience in a report on Thursday, January 22nd. Three investment analysts have rated the stock with a Buy rating and one has given a Hold rating to the company’s stock. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $16.00.

Niagen Bioscience Stock Performance

Shares of NASDAQ NAGE opened at $4.20 on Friday. The stock has a market cap of $336.34 million, a price-to-earnings ratio of 21.00 and a beta of 2.11. Niagen Bioscience has a fifty-two week low of $4.20 and a fifty-two week high of $14.69. The firm’s 50-day simple moving average is $5.22 and its 200 day simple moving average is $6.61.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently added to or reduced their stakes in NAGE. New York State Teachers Retirement System bought a new stake in Niagen Bioscience in the 4th quarter worth about $30,000. Financial Consulate Inc. purchased a new stake in Niagen Bioscience in the 3rd quarter valued at about $33,000. State of Alaska Department of Revenue bought a new position in shares of Niagen Bioscience during the 3rd quarter worth approximately $44,000. Ameritas Investment Partners Inc. bought a new position in shares of Niagen Bioscience during the 3rd quarter worth approximately $45,000. Finally, North Star Investment Management Corp. purchased a new position in shares of Niagen Bioscience in the 3rd quarter worth approximately $47,000. 15.41% of the stock is currently owned by hedge funds and other institutional investors.

Niagen Bioscience Company Profile

Niagen Bioscience, Inc is a global bioscience company, which engages in acquiring, developing, and commercializing proprietary-based ingredient technologies. It is pioneering research on nicotinamide adenine dinucleotide (NAD+). The company’s patent portfolio includes Nicotinamide Riboside (NR) and other NAD+ precursors, which are commercialized as the flagship ingredient Niagen. It operates through the following segments: Consumer Products, Ingredients, and Analytical Reference Standards and Services.